NCT04309526View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 18, 2020

Primary Completion Date

August 3, 2020

Study Completion Date

October 13, 2020

Conditions
Hepatitis B
Interventions
DRUG

NCO-48 Fumarate

NCO-48 Fumarate

DRUG

Placebo

Placebo

Trial Locations (1)

45227

Medpace Clinical Pharmacology Unit, Cincinnati

Sponsors
All Listed Sponsors
collaborator

Ligand Pharmaceuticals

INDUSTRY

collaborator

Medpace, Inc.

INDUSTRY

lead

Nucorion Pharmaceuticals, Inc.

INDUSTRY